Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics to Triple Sales Force

NEW YORK (GenomeWeb News) – Response Genetics said today that it intends to triple the size of its sales force in response to higher demand for its ResponseDx genetic testing services.
 
The Los Angeles-based firm did not disclose how many salespeople it currently employs.
 
According to Response Genetics, it has sold more than 500 of its ResponseDx: Lung and ResponseDx: Colon tests since their launch in September 2008. It said that sales figures have surpassed the firm’s initial goals. The firm also noted that it is experiencing a reorder rate of more than 90 percent for the PCR-based tests, which are offered through Response Genetics’ CLIA-certified lab and through NeoGenomics Laboratories, which inked a deal in September to offer the tests.
 
Response Genetics said that its sales force had initially focused on the California market, but with an expansion of its staff it plans to begin serving most major national markets.
 

Filed under

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.